BACKGROUND AND OBJECTIVES: Vascular calcification (VC) is common in CKD, but little is known about its prognostic effect on patients with nondialysis CKD. The prevalence of VC and its ability to predict death, time to hospitalization, and renal progression were assessed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Study of Mineral and Bone Disorders in CKD in Spain is a prospective, observational, 3-year follow-up study of 742 patients with nondialysis CKD stages 3-5 from 39 centers in Spain from April to May 2009. VC was assessed using Adragao (AS; x-ray pelvis and hands) and Kauppila (KS; x-ray lateral lumbar spine) scores from 572 and 568 patients, respectively. The primary end point was death. Secondary outcomes were hospital admissions and appearance of a combined renal end point (beginning of dialysis or drop >30% in eGFR). Factors related to VC were assessed by logistic regression analysis. Survival analysis was assessed by Cox proportional models. RESULTS: VC was present in 79% of patients and prominent in 47% (AS≥3 or KS>6). Age (odds ratio [OR], 1.05; 95% confidence interval [95% CI], 1.02 to 1.07; P<0.001), phosphorous (OR, 1.68; 95% CI, 1.28 to 2.20; P<0.001), and diabetes (OR, 2.11; 95% CI, 1.32 to 3.35; P=0.002) were independently related to AS≥3. After a median follow-up of 35 months (interquartile range=17-36), there were 70 deaths (10%). After multivariate adjustment for age, smoking, diabetes, comorbidity, renal function, and level of phosphorous, AS≥3 but not KS>6 was independently associated with all-cause (hazard ratio [HR], 2.07; 95% CI, 1.07 to 4.01; P=0.03) and cardiovascular (HR, 3.46; 95% CI, 1.27 to 9.45; P=0.02) mortality as well as a shorter hospitalization event-free period (HR, 1.14; 95% CI, 1.06 to 1.22; P<0.001). VC did not predict renal progression. CONCLUSIONS: VC is highly prevalent in patients with CKD. VC assessment using AS independently predicts death and time to hospitalization. Therefore, it could be a useful index to identify patients with CKD at high risk of death and morbidity as previously reported in patients on dialysis.
BACKGROUND AND OBJECTIVES:Vascular calcification (VC) is common in CKD, but little is known about its prognostic effect on patients with nondialysis CKD. The prevalence of VC and its ability to predict death, time to hospitalization, and renal progression were assessed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Study of Mineral and Bone Disorders in CKD in Spain is a prospective, observational, 3-year follow-up study of 742 patients with nondialysis CKD stages 3-5 from 39 centers in Spain from April to May 2009. VC was assessed using Adragao (AS; x-ray pelvis and hands) and Kauppila (KS; x-ray lateral lumbar spine) scores from 572 and 568 patients, respectively. The primary end point was death. Secondary outcomes were hospital admissions and appearance of a combined renal end point (beginning of dialysis or drop >30% in eGFR). Factors related to VC were assessed by logistic regression analysis. Survival analysis was assessed by Cox proportional models. RESULTS: VC was present in 79% of patients and prominent in 47% (AS≥3 or KS>6). Age (odds ratio [OR], 1.05; 95% confidence interval [95% CI], 1.02 to 1.07; P<0.001), phosphorous (OR, 1.68; 95% CI, 1.28 to 2.20; P<0.001), and diabetes (OR, 2.11; 95% CI, 1.32 to 3.35; P=0.002) were independently related to AS≥3. After a median follow-up of 35 months (interquartile range=17-36), there were 70 deaths (10%). After multivariate adjustment for age, smoking, diabetes, comorbidity, renal function, and level of phosphorous, AS≥3 but not KS>6 was independently associated with all-cause (hazard ratio [HR], 2.07; 95% CI, 1.07 to 4.01; P=0.03) and cardiovascular (HR, 3.46; 95% CI, 1.27 to 9.45; P=0.02) mortality as well as a shorter hospitalization event-free period (HR, 1.14; 95% CI, 1.06 to 1.22; P<0.001). VC did not predict renal progression. CONCLUSIONS: VC is highly prevalent in patients with CKD. VC assessment using AS independently predicts death and time to hospitalization. Therefore, it could be a useful index to identify patients with CKD at high risk of death and morbidity as previously reported in patients on dialysis.
Authors: Martijn L L Chatrou; Kristien Winckers; Tilman M Hackeng; Chris P Reutelingsperger; Leon J Schurgers Journal: Blood Rev Date: 2012-04-18 Impact factor: 8.250
Authors: Renato Watanabe; Marcelo M Lemos; Silvia R Manfredi; Sérgio A Draibe; Maria Eugênia F Canziani Journal: Clin J Am Soc Nephrol Date: 2009-12-03 Impact factor: 8.237
Authors: Kristin M McCabe; Sarah L Booth; Xueyan Fu; Navid Shobeiri; Judith J Pang; Michael A Adams; Rachel M Holden Journal: Kidney Int Date: 2013-01-23 Impact factor: 10.612
Authors: Pablo Molina; José L Górriz; Mariola D Molina; Sandra Beltrán; Belén Vizcaíno; Verónica Escudero; Julia Kanter; Ana I Ávila; Jordi Bover; Elvira Fernández; Javier Nieto; Secundino Cigarrán; Enrique Gruss; Gema Fernández-Juárez; Alberto Martínez-Castelao; Juan F Navarro-González; Ramón Romero; Luis M Pallardó Journal: World J Nephrol Date: 2016-09-06
Authors: Wei Chen; Viktoriya Anokhina; Gregory Dieudonne; Matthew K Abramowitz; Randeep Kashyap; Chen Yan; Tong Tong Wu; Karen L de Mesy Bentley; Benjamin L Miller; David A Bushinsky Journal: Nephrol Dial Transplant Date: 2019-06-01 Impact factor: 5.992
Authors: Pablo Molina; Mariola D Molina; Luis M Pallardó; Javier Torralba; Verónica Escudero; Luis Álvarez; Ana Peris; Pilar Sánchez-Pérez; Miguel González-Rico; María J Puchades; José E Fernández-Nájera; Elena Giménez-Civera; Luis D'Marco; Juan J Carrero; José L Górriz Journal: J Nephrol Date: 2021-01-04 Impact factor: 3.902
Authors: Andreas Pasch; Geoffrey A Block; Matthias Bachtler; Edward R Smith; Wilhelm Jahnen-Dechent; Spyridon Arampatzis; Glenn M Chertow; Patrick Parfrey; Xiaoye Ma; Juergen Floege Journal: Clin J Am Soc Nephrol Date: 2016-12-09 Impact factor: 8.237